National polling indicates 54% of rural adults face at least one healthcare access barrier, underscoring that “access” is multidimensional and differs from coverage-centric system design. High cost ...

Formulary exclusions have expanded from ~30 to ~1,400 in a decade, reflecting insurer responses to crowded classes and accelerating the migration of certain brands toward cash channels. Retail step ...

Enforcement of the Drug Supply Chain Security Act—otherwise known as DSCSA—is currently in full swing. After the FDA ruled that it would enact phased deadlines for compliance this year, manufacturers ...

Shawn Seamans, Chief Commercial Officer, CoverMyMeds | Authors | Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking ...

Geopolitical supply chain mapping identifies hidden dependencies across corridors, ports, airports, customs gateways, and carriers that can undermine continuity despite apparent supplier ...

Wilhelm's comments describe a supply chain strategy built around flexibility, balancing inventory positioned close to ...

Embedding access tools at prescribing reduces manual enrollment, portal switching, and late activation, enabling faster ...

Amy Niles of the Patient Advocate Foundation revisits her 2026 outlook on prior authorization reform and the Medicare Prescription Payment Plan. Pharmaceutical Commerce continues its H1 Review/H2 ...

Rising U.S. prescription spending heightens urgency to identify when to trigger clinical review, discontinue payment, or shift to lower-cost options before avoidable spend accrues. “Subtraction ...

In this week's Pharma Pulse, Cardinal Health expands its at-Home Solutions business with two acquisitions, President Trump lays out a phased tariff schedule for generic drugs, and Novo Nordisk sues ...

Medicaid work requirements under the One Big Beautiful Bill Act demand employment/volunteering documentation and clinician attestations, while exemption severity criteria vary by state and may be ...

Claims target comparative ads that juxtapose tirzepatide’s maximum tolerated doses with semaglutide regimens that omit FDA-approved higher strengths, potentially creating a misleading efficacy ...